Biogen (BIIB) Receivables - Other (2009 - 2023)

Biogen (BIIB) has reported Receivables - Other for 9 consecutive years, with $6.3 million the latest figure, recorded in Q1 2023.

• In Q1 2023, Receivables - Other rose 8.62% year-over-year to $6.3 million; the TTM figure through Mar 2023 stood at $6.3 million (up 8.62% YoY), while the FY2022 annual figure was $2.0 million, down 51.22% from the prior year.
• Receivables - Other came in at $6.3 million for Q1 2023 at Biogen, up from $2.0 million in the prior quarter.
• The five-year high for Receivables - Other was $110.6 million in Q3 2022, with the low at $2.0 million in Q4 2022.
• Average Receivables - Other over 5 years is $22.1 million, with a median of $5.1 million recorded in 2020.
• Across the five-year window, Receivables - Other plunged 94.0% in 2020 and gained 8.62% in 2023, its largest moves.
• Year by year, Receivables - Other stood at $85.0 million in 2019, then slumped by 94.0% to $5.1 million in 2020, then slipped by 19.61% to $4.1 million in 2021, then tumbled by 51.22% to $2.0 million in 2022, then jumped by 215.0% to $6.3 million in 2023.
• According to Business Quant data, Receivables - Other over the past three periods registered $6.3 million, $2.0 million, and $110.6 million for Q1 2023, Q4 2022, and Q3 2022 respectively.